Last reviewed · How we verify
NCT06353035: BIWE
Biodiversity Interventions for Well-Being
NA trial testing Rewilding in Microbial Colonization in 30 participants. Participants enrolled and being followed up; not accepting new ones.
30 June 2027
Quick facts
| Lead sponsor | Natural Resources Institute Finland |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 30 |
| Start date | 30 March 2022 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across Finland |
Drugs / interventions tested
- Rewilding
Conditions studied
- Microbial Colonization — all drugs for Microbial Colonization →
- Immune System Diseases — all drugs for Immune System Diseases →
- Well-Being, Psychological — all drugs for Well-Being, Psychological →
- Nature, Human — all drugs for Nature, Human →
Sponsor
Natural Resources Institute Finland
Who can join
Adults 18 to 72, any sex, with Microbial Colonization or Immune System Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities, which weakens the functionality of the urban ecosystems and the well-being of citizens. This may also increase the risk of immune-mediated disorders among urban dwellers. In Biodiversity interventions for well-being (BIWE), microbial biodiversity interventions are performed to increase biodiversity in urban built areas. Results from the intervention trials are combined with publicly available land cover and ecological data. These are analyzed from the viewpoint of shifts in ecosystems and human well-being and immune regulation, ecological quality, and urban planning. The investigators set up an intervention study in which urban private yards are rewilded with diverse vegetation and decaying deadwood and plant residuals. The investigators aim to evaluate the effect of rewilding, and yard management practices on commensal microbiome, cortisol levels and well-being and salivary cytokine levels, and gene pathways.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06353035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rewilding
Trials testing the same drug.
- NCT06390683 — Biodiversity Interventions for Assisted Living Centers · NA · active not recruiting
Other recruiting trials for Microbial Colonization
Currently open trials in the same condition.
- NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
- NCT06805994 — Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment · Phase 1 · recruiting
- NCT06938386 — Pilot Haskap Metabolite Timing Project · NA · active not recruiting
- NCT06920641 — Effects of Tagatose on Glycemic Response and Gastrointestinal Microbiota in Healthy Adults · NA · recruiting
- NCT06541808 — Balance, Autonomic Response, and Sensory Modulation to Dosage of Mechanical Vagal Stimulation in Healthy Adults · NA · recruiting
Other Natural Resources Institute Finland trials
Trials by the same sponsor.
- NCT06390878 — Nationwide Research on the Rewilding of Kindergarten Yards · NA · recruiting
- NCT06390696 — Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis · NA · recruiting
- NCT06390683 — Biodiversity Interventions for Assisted Living Centers · NA · active not recruiting
- NCT03794141 — Genetic Information as a Life Style Change Motivator · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06353035 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Natural Resources Institute Finland
- Last refreshed: 8 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06353035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing